Overview
GLMD market data
Price History
GLMD price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$8.09 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.59 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -424.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.41 – $1.65 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.6M · P/B 0.26 · P/S 2.00.
Company News
Galmed Pharma Announces Continued Advancement Of Aramchol As Potential Disease-Modifying Therapy For Parkinson's Disease, Reporting Significant Progress In Development Of New Aramchol ODF FormulationBenzinga · Jul 28, 2026, 11:09 AM
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving PremarketBenzinga · Jul 21, 2026, 9:11 AM
Galmed Pharmaceuticals shares are trading higher after the company announced the development of a new Aramchol-based lipid nanoparticles formulation for targeted delivery to the heart.Benzinga · Jul 16, 2026, 6:00 PM
Galmed Pharmaceuticals Announces Breakthrough Development Of New Aramchol-Based Lipid Nanoparticles Formulation For Targeted Delivery To The HeartBenzinga · Jul 16, 2026, 11:35 AM
Galmed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS"Benzinga · Jul 1, 2026, 8:05 PM
Galmed Agrees With Acquisition Target Colospan To Increase The Cash Portion Of Purchase Price By $800K In Lieu Of Issuing $2M In SharesBenzinga · Jun 22, 2026, 11:35 AM
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion MarketBenzinga · Jun 8, 2026, 1:15 PM
Galmed Pharmaceuticals Signs Agreement To Acquire Medical Device Firm Colospan For $2.5M In Cash, $2M Galmed SharesBenzinga · Jun 8, 2026, 12:20 PM
UK's MHRA Says Resmetirom (Rezdiffra) Authorized To Treat Metabolic Dysfunction-Associated Steatohepatitis In AdultsBenzinga · Jun 3, 2026, 3:35 PM
Galmed Reports Preclinical Results for Heart Disease Drug Combination, Study Identifies New Pathway Linked to Cardiac FibrosisBenzinga · Jun 2, 2026, 11:38 AM